How I treat patients with myelodysplastic syndromes.
Stone
Richard M
RM
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. rstone@partners.org
D000208:Acute Disease; D000368:Aged; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015913:Chelation Therapy; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000648:ultrastructure; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D018450:Disease Progression; D004921:Erythropoietin / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D007951:Leukemia, Myeloid / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012720:Severity of Illness Index; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014184:Transplantation, Homologous
D016298:Hematopoietic Cell Growth Factors; D007502:Iron Chelating Agents; D004921:Erythropoietin; D013792:Thalidomide; D000077209:Decitabine; D000077269:Lenalidomide; D001374:Azacitidine